Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

BMI - Olivier Le Moal
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link

November 21st 2024

A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.

Doctor examining MRI images of multiple sclerosis MS | Image Credit: © New Africa - stock.adobe.com
Lesion Repair, Damage Processes Correlate With MS Disease Characteristics

November 11th 2024

Neurologic disease concept | image credit: ralwel - stock.adobe.com
Fexagratinib in MS Shows Promise for Human Use

November 9th 2024

MS word cloud | Image Credit: © arloo-stock.adobe.com
Exploring Metabolic Links to Cognitive Impairment in MS

November 8th 2024

Fingolimod | Image Credit: © María Pilar Martínez - stock.adobe.com
Fingolimod-Induced Heart Rate Slowing Tied to Parasympathetic Dominance in MS

October 26th 2024

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
November 24th 2024

Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care

1.5 Credits / Neurology
November 24th 2024

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
November 24th 2024

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
November 24th 2024

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
November 24th 2024

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

More News

Rituximab Shows Clinical Benefit in Treating Both Progressive and Relapsing-Remitting MS
June 15th 2018

Rituximab Shows Clinical Benefit in Treating Both Progressive and Relapsing-Remitting MS

Samantha DiGrande
Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) in a single tertiary care center in Switzerland.
MS Drug Reduces Risk of Disability Progression in Phase 3 Study
June 13th 2018

MS Drug Reduces Risk of Disability Progression in Phase 3 Study

Alison Rodriguez
Long-term treatment of patients with secondary progressive multiple sclerosis (SPMS) with siponimod may reduce the risk of disability progression, according to findings of the phase 3 EXPAND study.
Updated Clinical Trial Results and Approval Progress for MS Ocrelizumab Treatment
June 8th 2018

Updated Clinical Trial Results and Approval Progress for MS Ocrelizumab Treatment

Alison Rodriguez
Ocrelizumab (Ocrevus) has been FDA approved for the treatment of primary progressive multiple sclerosis, and recent clinical trials with the anti-CD20 monoclonal antibody have revealed significant decreases in disease activity and disability progression in relapsing multiple sclerosis.
MS Drug Could Reduce Adverse Events Associated With Cancer Treatment
June 4th 2018

MS Drug Could Reduce Adverse Events Associated With Cancer Treatment

Samantha DiGrande
In a recent study published in the Journal of Experimental Medicine, researchers found that fingolimod (sold as Gilenya), an FDA-approved orally administered drug to treat multiple sclerosis, could reduce painful side effects of multiple myeloma treatments.
Study Identifies New Pathway to Guide Therapies for MS
May 31st 2018

Study Identifies New Pathway to Guide Therapies for MS

Alison Rodriguez
Researchers from Brigham and Women’s Hospital (BWH) have defined a new pathway that may help guide therapies for multiple sclerosis and other neurologic diseases.
Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019
May 27th 2018

Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019

There's the potential for new nonalcoholic fatty liver disease and multiple sclerosis drugs to be approved in 2019, said Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts.
Site Logo
May 11th 2018

Researcher Details Microbiome Mysteries Connecting the Gut, Brain

Allison Inserro
Our knowledge of the human microbiome has only been developed over the past decade, according to Elaine Hsaio, PhD, assistant professor of integrative biology and physiology at the University of California, Los Angeles, at the 73rd Annual Scientific Convention of the Society of Biological Psychiatry meeting in New York City, May 10 to 12. Hsaio presented about how the microbiome influences brain function, development and behavior.
Ian Manners Explains How Vivor Empowers Providers and Financial Navigators
May 3rd 2018

Ian Manners Explains How Vivor Empowers Providers and Financial Navigators

Vivor helps patients receive financial assistance by focusing on empowering the providers and making it easier for financial navigators to do their job, said Ian Manners, founder and CEO of Vivor.
Site Logo
April 24th 2018

Specialty Drug Pipeline Review Focuses on Competition, Cancer Drugs

Allison Inserro
At the Academy of Managed Care Pharmacy's Managed Care & Specialty Pharmacy Annual Meeting, held April 23-26, in Boston, Massachusetts, an overflow capacity crowd gathered for one of the meeting’s yearly highlights­: Specialty Pharmaceuticals in Development. Aimee Tharaldson, PharmD, a senior clinical consultant in Emerging Therapeutics for Express Scripts, talked about the key trends in the specialty drug market, including cancer drugs, new competition, and orphan drugs.
Siponimod Reduced Progression in Secondary Progressive Multiple Sclerosis in a Phase 3 Trial
April 1st 2018

Siponimod Reduced Progression in Secondary Progressive Multiple Sclerosis in a Phase 3 Trial

Kelly Davio
Results of a double-blind, randomized, phase 3 trial, published last week in The Lancet, show that siponimod—a selective sphingosine 1-phosphate receptor modulator—slowed the progression of disability in secondary progressive multiple sclerosis.
AJMC® in the Press, March 30, 2018
March 30th 2018

AJMC® in the Press, March 30, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Site Logo
August 18th 2017

What We're Reading: Mylan Settlement; MS Pricing Probe; Iowa Insurer's Premium Rate Hike

AJMC Staff
Site Logo
August 18th 2017

Understanding Patient Preferences Can Promote Adherence in MS Patients, Study Says

Alison Rodriguez
Patient preferences for multiple sclerosis therapies are important to take into account and are increasingly so as alternatives to traditional injection therapies are developed to address adherence issues.
Site Logo
July 26th 2017

Patient Questionnaires Can Predict Clinical Outcomes in Patients With Multiple Sclerosis

Alison Rodriguez
Patient-reported outcomes (PROs) can demonstrate the effects of a disease or treatment. By using patient questionnaires, the results can be analyzed to predict clinical outcomes in medical research for diseases, including multiple sclerosis (MS).
Site Logo
June 23rd 2017

Genentech's Ocrevus Reduces Disease Progression in Multiple Sclerosis Patients

Alison Rodriguez
A phase 3 clinical trial of patients with relapsing multiple sclerosis and primary progressive multiple sclerosis found that Ocrevus (ocrelizumab) significantly reduced disease progression, according to results released by Genentech.
Dr Aimee Tharaldson Highlights Two Key Drugs for 2017
March 28th 2017

Dr Aimee Tharaldson Highlights Two Key Drugs for 2017

The first drug to treat primary progressive multiple sclerosis and a new drug approved for atopic dermatitis are the 2017 approvals most exciting to Aimee Tharaldson, PharmD, of Express Scripts.
Site Logo
February 21st 2017

Survey Finds Varied Views on Value of Multiple Sclerosis Therapies

AJMC Staff
Population-level judgements on the value of therapies to treat multiple sclerosis don’t adequately depict the differences between how providers and payers view value compared with patients and how patients view value different from one another.
Site Logo
February 16th 2017

Experimental Treatment Induces Remission in Multiple Sclerosis

Laura Joszt, MA
A new treatment option using stem cell transplants was shown to induce sustained remission of relapsing-remitting multiple sclerosis (MS). More than two-thirds of participants had no signs of progression of disability, relapse of MS symptoms, or new brain lesions after 5 years.
Site Logo
February 2nd 2017

Analysis Finds Alemtuzumab Most Cost-Effective Treatment for Multiple Sclerosis

Laura Joszt, MA
A review of 15 disease-modifying therapies (DMTs) for the treatment of relapsing-remitting and primary-progressive multiple sclerosis (MS) has found that prices for most of these drugs are not well-aligned with added value for patients.
Site Logo
February 1st 2017

What We're Reading: Aetna's ACA Future, Teva Loses MS Patent, and Hawaii Saves Parts of ACA

AJMC Staff
Site Logo
November 14th 2016

Genes, the Environment, and Autoimmune Disease

David Hafler, MD, chairman of the Department of Neurology at the Yale School of Medicine, spoke of exciting times in the field of genome-wide association study-specifically speaking to neurology, genetics, the environment, and the autoimmune response.
Site Logo
November 11th 2016

AJMC in the Press, November 11, 2016

AJMC Staff
A review of our peer-reviewed research in the healthcare and mainstream press.
Site Logo
October 26th 2016

Reconsidering the Economic Value of Multiple Sclerosis Therapies

Tiffany Shih, PhD Craig Wakeford, MA Dennis Meletiche, PharmD Jesse Sussell, PhD Adrienne Chung, PhD Yanmei Liu, MS Jin Joo Shim, MS Darius Lakdawalla, PhD
Availability of multiple sclerosis (MS) therapies provides substantial value to the currently healthy (who may contract MS in the future), particularly when treatment is fully covered by insurance.
Site Logo
October 11th 2016

OOP Expenses Remain a Problem in Medicare, Especially for Beneficiaries Taking Specialty Drugs

Priyam Vora
Medicare beneficiaries still face huge out-of-pocket expenses because of uncapped cost sharing in the catastrophic coverage phase. This is especially true for beneficiaries who take specialty drugs.
Site Logo
June 1st 2016

Current and Emerging Treatment of Multiple Sclerosis

Felecia M. Hart, PharmD Jacquelyn Bainbridge, BSPharm, PharmD
Site Logo
May 31st 2016

Cost-Effectiveness of Disease- Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective

Site Logo
May 31st 2016

Economic Burden of Multiple Sclerosis and the Role of Managed Care Organizations in Multiple Sclerosis Management

Gary M. Owens, MD
Site Logo
May 13th 2016

Significant Toxicity of Mitoxantrone in Patients With Multiple Sclerosis: Cancer

Surabhi Dangi-Garimella, PhD
Researchers in Germany have discovered that mitoxantrone-used to treat aggressive, relapsing, or progressive multiple sclerosis-can increase the risk of leukemia and colorectal cancer in those being treated.
Two Drugs Dr Aimee Tharaldson Is Watching Closely in 2016
April 21st 2016

Two Drugs Dr Aimee Tharaldson Is Watching Closely in 2016

Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, outlined the 2 pipeline drugs she is keeping a close eye on in 2016: both are breakthrough therapies and one could have a significant impact on the market.
Site Logo
March 18th 2016

The MS Center of Saint Louis: A Practice Perspective of the Impacts of High Cost Sharing

Katherine Upshur, MSW, LCSW
This case study from the MS Center of Saint Louis examines how patients are impacted by high healthcare costs and addresses potential solutions to this problem.
<1
...
12131415161718192021>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo